Hideaki Ijichi

List of Publications by Year
in descending order

131	4,941	87723	98622
papers	citations	38 h-index	67 g-index

137	137	137	8354
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression. Genes and Development, 2006, 20, 3147-3160.	2.7	326
2	PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. New England Journal of Medicine, 2015, 373, 1979-1979.	13.9	314
3	Loss of 5â€hydroxymethylcytosine is accompanied with malignant cellular transformation. Cancer Science, 2012, 103, 670-676.	1.7	241
4	Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. Journal of Clinical Investigation, 2011, 121, 4106-4117.	3.9	216
5	Blockade of the Stromal Cellâ€"Derived Factor-1/CXCR4 Axis Attenuates In vivo Tumor Growth by Inhibiting Angiogenesis in a Vascular Endothelial Growth Factorâ€"Independent Manner. Cancer Research, 2005, 65, 5864-5871.	0.4	178
6	Long-term Risk of Malignancy in Branch-Duct Intraductal Papillary Mucinous Neoplasms. Gastroenterology, 2020, 158, 226-237.e5.	0.6	160
7	Inhibition of reninâ€"angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. British Journal of Cancer, 2010, 103, 1644-1648.	2.9	150
8	Vitamin K2inhibits the growth and invasiveness of hepatocellular carcinoma cells via protein kinase A activation. Hepatology, 2004, 40, 243-251.	3.6	124
9	Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. Cancer Research, 2003, 63, 8132-7.	0.4	124
10	Loss of liver E-cadherin induces sclerosing cholangitis and promotes carcinogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 1090-1095.	3.3	104
11	Regulation of the hedgehog signaling by the mitogenâ€activated protein kinase cascade in gastric cancer. Molecular Carcinogenesis, 2009, 48, 703-712.	1.3	103
12	Interaction of the hepatitis B virus X protein (HBx) with heat shock protein 60 enhances HBx-mediated apoptosis. Biochemical and Biophysical Research Communications, 2004, 318, 461-469.	1.0	94
13	The hepatitis B virus X protein enhances AP-1 activation through interaction with Jab1. Oncogene, 2006, 25, 633-642.	2.6	88
14	p53-Independent Negative Regulation of p21/Cyclin-Dependent Kinaseâ€"Interacting Protein 1 by the Sonic Hedgehog-Glioma-Associated Oncogene 1 Pathway in Gastric Carcinoma Cells. Cancer Research, 2005, 65, 10822-10829.	0.4	86
15	Loss of histone demethylase KDM6B enhances aggressiveness of pancreatic cancer through downregulation of C/EBPÎ±. Carcinogenesis, 2014, 35, 2404-2414.	1.3	83
16	Decreased Expression of the RAS-GTPase Activating Protein RASAL1 Is Associated With Colorectal Tumor Progression. Gastroenterology, 2009, 136, 206-216.	0.6	80
17	Smad4-independent regulation of p21/WAF1 by transforming growth factor-Î². Oncogene, 2004, 23, 1043-1051.	2.6	76
18	Different subtypes of intraductal papillary mucinous neoplasm in the pancreas have distinct pathways to pancreatic cancer progression. Journal of Gastroenterology, 2012, 47, 203-213.	2.3	73

#	Article	IF	Citations
19	Blocking CXCLsâ€“CXCR2 axis in tumorâ€“stromal interactions contributes to survival in a mouse model of pancreatic ductal adenocarcinoma through reduced cell invasion/migration and a shift of immune-inflammatory microenvironment. Oncogenesis, 2019, 8, 8.	2.1	73
20	Smad4 silencing in pancreatic cancer cell lines using stable RNA interference and gene expression profiles induced by transforming growth factor-Î². Oncogene, 2005, 24, 662-671.	2.6	72
21	Different Effects of Point Mutations within the B-Raf Glycine-Rich Loop in Colorectal Tumors on Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase/Extracellular Signal-Regulated Kinase and Nuclear Factor ÎºB Pathway and Cellular Transformation. Cancer Research, 2004, 64, 3428-3435.	0.4	69
22	Biliary epithelial injury-induced regenerative response by IL-33 promotes cholangiocarcinogenesis from peribiliary glands. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E3806-E3815.	3.3	65
23	Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer. Oncotarget, 2016, 7, 61469-61484.	0.8	64
24	Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion. Biochemical and Biophysical Research Communications, 2010, 394, 1042-1046.	1.0	61
25	Systematic Analysis of the TGF-Î²-Smad Signaling Pathway in Gastrointestinal Cancer Cells. Biochemical and Biophysical Research Communications, 2001, 289, 350-357.	1.0	60
26	Incidence of extrapancreatic malignancies in patients with intraductal papillary mucinous neoplasms of the pancreas. Gut, 2011, 60, 1249-1253.	6.1	60
27	A novel mouse model of intrahepatic cholangiocarcinoma induced by liver-specific Kras activation and Pten deletion. Scientific Reports, 2016, 6, 23899.	1.6	60
28	Altered composition of fatty acids exacerbates hepatotumorigenesis during activation of the phosphatidylinositol 3-kinase pathway. Journal of Hepatology, 2011, 55, 1400-1408.	1.8	57
29	Clinical Outcomes of Chemotherapy for Diabetic and Nondiabetic Patients With Pancreatic Cancer. Pancreas, 2013, 42, 202-208.	0.5	54
30	Loss of Transforming Growth Factor Beta Type II Receptor Increases Aggressive Tumor Behavior and Reduces Survival in Lung Adenocarcinoma and Squamous Cell Carcinoma. Clinical Cancer Research, 2012, 18, 2173-2183.	3.2	52
31	Apoptosis Signal-Regulating Kinase 1 Regulates Colitis and Colitis-Associated Tumorigenesis by the Innate Immune Responses. Gastroenterology, 2010, 138, 1055-1067.e4.	0.6	50
32	Single small-interfering RNA expression vector for silencing multiple transforming growth factor-Â pathway components. Nucleic Acids Research, 2005, 33, e131-e131.	6.5	47
33	Erlotinib Prolongs Survival in Pancreatic Cancer by Blocking Gemcitabine-Induced MAPK Signals. Cancer Research, 2013, 73, 2221-2234.	0.4	47
34	Analysis of the Î²-Catenin/T Cell Factor Signaling Pathway in 36 Gastrointestinal and Liver Cancer Cells. Japanese Journal of Cancer Research, 2002, 93, 1213-1220.	1.7	46
35	A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2. Investigational New Drugs, 2013, 31, 1294-1299.	1.2	45
36	Engineering fibrotic tissue in pancreatic cancer: A novel three-dimensional model to investigate nanoparticle delivery. Biochemical and Biophysical Research Communications, 2012, 419, 32-37.	1.0	40

#	Article	IF	Citations
37	Risk factors and early signs of pancreatic cancer in diabetes: screening strategy based on diabetes onset age. Journal of Gastroenterology, 2013, 48, 238-246.	2.3	40
38	Histone demethylase KDM4C regulates sphere formation by mediating the cross talk between Wnt and Notch pathways in colonic cancer cells. Carcinogenesis, 2013, 34, 2380-2388.	1.3	40
39	Smad4 is Essential for Down-regulation of E-cadherin Induced by TGF-Â in Pancreatic Cancer Cell Line PANC-1. Journal of Biochemistry, 2006, 141, 345-351.	0.9	38
40	Impact of histone demethylase KDM3A-dependent AP-1 transactivity on hepatotumorigenesis induced by PI3K activation. Oncogene, 2017, 36, 6262-6271.	2.6	38
41	Satellite RNAs promote pancreatic oncogenic processes via the dysfunction of YBX1. Nature Communications, 2016, 7, 13006.	5.8	37
42	Phase I trial of gemcitabine and candesartan combination therapy in normotensive patients with advanced pancreatic cancer: <scp>GECA</scp>1. Cancer Science, 2012, 103, 1489-1492.	1.7	36
43	Therapeutic effect of câ€Jun Nâ€terminal kinase inhibition on pancreatic cancer. Cancer Science, 2013, 104, 337-344.	1.7	36
44	Photoacoustic Tomography of Human Hepatic Malignancies Using Intraoperative Indocyanine Green Fluorescence Imaging. PLoS ONE, 2014, 9, e112667.	1.1	36
45	Pancreatic Cancer With Malignant Ascites. Pancreas, 2015, 44, 380-385.	0.5	35
46	Identification of a Suppressive Mechanism for Hedgehog Signaling through a Novel Interaction of Gli with 14-3-3. Journal of Biological Chemistry, 2010, 285, 4185-4194.	1.6	34
47	Impact of S-1 in Patients with Gemcitabine-refractory Pancreatic Cancer in Japan. Japanese Journal of Clinical Oncology, 2010, 40, 774-780.	0.6	34
48	Prevalence of Pancreatic Cystic Lesions Is Associated With Diabetes Mellitus and Obesity. Pancreas, 2017, 46, 801-805.	0.5	34
49	Proteomic analysis of the TGF-Î² signaling pathway in pancreatic carcinoma cells using stable RNA interference to silence Smad4 expression. Biochemical and Biophysical Research Communications, 2004, 318, 289-296.	1.0	33
50	Risk for Mortality From Causes Other Than Pancreatic Cancer in Patients With Intraductal Papillary Mucinous Neoplasm of the Pancreas. Pancreas, 2013, 42, 687-691.	0.5	33
51	Genetically-engineered mouse models for pancreatic cancer: Advances and current limitations. World Journal of Clinical Oncology, 2011, 2, 195.	0.9	31
52	TGF-Î² Signaling in Dendritic Cells Governs Colonic Homeostasis by Controlling Epithelial Differentiation and the Luminal Microbiota. Journal of Immunology, 2016, 196, 4603-4613.	0.4	30
53	A Pilot Study for Combination Chemotherapy Using Gemcitabine and S-1 for Advanced Pancreatic Cancer. Oncology, 2009, 77, 300-303.	0.9	28
54	Impact of S-1 on the Survival of Patients With Advanced Pancreatic Cancer. Pancreas, 2010, 39, 989-993.	0.5	27

#	Article	IF	Citations
55	Sharpin promotes hepatocellular carcinoma progression via transactivation of Versican expression. Oncogenesis, 2016, 5, e277-e277.	2.1	27
56	Blocking VCAM-1 inhibits pancreatic tumour progression and cancer-associated thrombosis/thromboembolism. Gut, 2021, 70, 1713-1723.	6.1	27
57	Abstract 4383: Targeting tumor microenvironment with gemcitabine is useful for the treatment of pancreatic ductal adenocarcinoma. , 2012, , .		25
58	Frameshift Mutations at Mononucleotide Repeats inRAD50Recombinational DNA Repair Gene in Colorectal Cancers with Microsatellite Instability. Japanese Journal of Cancer Research, 2001, 92, 587-591.	1.7	23
59	Reduced expression of RAS protein activator likeâ€1 in gastric cancer. International Journal of Cancer, 2011, 128, 1293-1302.	2.3	22
60	Recent progress and limitations of chemotherapy for pancreatic and biliary tract cancers. World Journal of Clinical Oncology, 2011, 2, 158.	0.9	22
61	Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monotherapy for refractory pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2013, 71, 85-92.	1.1	21
62	The inhibition of renin-angiotensin system in advanced pancreatic cancer: an exploratory analysis in 349 patients. Journal of Cancer Research and Clinical Oncology, 2015, 141, 933-939.	1.2	21
63	Diabetes is a useful diagnostic clue to improve the prognosis of pancreatic cancer. Pancreatology, 2013, 13, 285-289.	0.5	20
64	Overexpression of HER2 in the pancreas promotes development of intraductal papillary mucinous neoplasms in mice. Scientific Reports, 2018, 8, 6150.	1.6	20
65	Smoking, Family History of Cancer, and Diabetes Mellitus Are Associated With the Age of Onset of Pancreatic Cancer in Japanese Patients. Pancreas, 2014, 43, 1014-1017.	0.5	19
66	Inhibition of histone methyltransferase G9a attenuates liver cancer initiation by sensitizing DNA-damaged hepatocytes to p53-induced apoptosis. Cell Death and Disease, 2021, 12, 99.	2.7	19
67	3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor simvastatin ameliorates renal fibrosis through HOXA13â€“USAG-1 pathway. Laboratory Investigation, 2012, 92, 1161-1170.	1.7	18
68	Intravenous and Intraperitoneal Paclitaxel with S-1 for Refractory Pancreatic Cancer with Malignant Ascites: an Interim Analysis. Journal of Gastrointestinal Cancer, 2014, 45, 307-311.	0.6	18
69	Indirubin 3â€²-Oxime Inhibits Migration, Invasion, and Metastasis in Mice Bearing Spontaneously Occurring Pancreatic Cancer via Blocking the RAF/ERK, AKT, and SAPK/JNK Pathways. Translational Oncology, 2019, 12, 1574-1582.	1.7	18
70	Mutant IDH1 confers resistance to energy stress in normal biliary cells through PFKP-induced aerobic glycolysis and AMPK activation. Scientific Reports, 2019, 9, 18859.	1.6	18
71	Midazolam exhibits antitumour and anti-inflammatory effects in a mouse model of pancreatic ductal adenocarcinoma. British Journal of Anaesthesia, 2022, 128, 679-690.	1.5	18
72	Inhibition of CXCLs/CXCR2 axis in the tumor microenvironment might be a potent therapeutics for pancreatic cancer. OncoImmunology, 2012, 1, 569-571.	2.1	17

#	Article	IF	Citations
73	Isocitrate dehydrogenase 1 mutation sensitizes intrahepatic cholangiocarcinoma to the <scp>BET</scp> inhibitor <scp>JQ</scp>1. Cancer Science, 2018, 109, 3602-3610.	1.7	17
74	False positive uptake of metaiodobenzylguanidine in hepatocellular carcinoma. British Journal of Radiology, 2002, 75, 548-551.	1.0	16
75	Runx3 interacts with DNA repair protein Ku70. Experimental Cell Research, 2007, 313, 3251-3260.	1.2	16
76	A retrospective analysis of early CA19-9 change in salvage chemotherapy for refractory pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2013, 72, 1291-1297.	1.1	16
77	Disease-Specific Mortality Among Patients With Intraductal Papillary Mucinous Neoplasm of the Pancreas. Clinical Gastroenterology and Hepatology, 2014, 12, 486-491.	2.4	16
78	Adhesive Interactions between Mononuclear Phagocytes and Intestinal Epithelium Perturb Normal Epithelial Differentiation and Serve as a Therapeutic Target in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2018, 12, 1219-1231.	0.6	16
79	MNX1-HNF1B Axis Is Indispensable for Intraductal Papillary Mucinous Neoplasm Lineages. Gastroenterology, 2022, 162, 1272-1287.e16.	0.6	16
80	Fuel economy of multigrade gear lubricants. Industrial Lubrication and Tribology, 2000, 52, 165-173.	0.6	15
81	Rapid detection of mutations in the BRAF gene using real-time polymerase chain reaction and melting curve analysis. Cancer Genetics and Cytogenetics, 2004, 149, 68-71.	1.0	15
82	A potent therapeutics for gallbladder cancer by combinatorial inhibition of the MAPK and mTOR signaling networks. Journal of Gastroenterology, 2016, 51, 711-721.	2.3	15
83	Soluble VCAM-1 promotes gemcitabine resistance via macrophage infiltration and predicts therapeutic response in pancreatic cancer. Scientific Reports, 2020, 10, 21194.	1.6	14
84	Duloxetine improves cancer-associated pain in a mouse model of pancreatic cancer through stimulation of noradrenaline pathway and its antitumor effects. Pain, 2020, 161, 2909-2919.	2.0	14
85	TRAIL-induced cell death cooperates with IFN-Î³ activation in the graft-versus-tumor effect against colon tumors. International Journal of Cancer, 2006, 118, 2237-2246.	2.3	13
86	A phase II trial of gemcitabine, S-1 and LV combination (GSL) neoadjuvant chemotherapy for patients with borderline resectable and locally advanced pancreatic cancer. Medical Oncology, 2018, 35, 100.	1.2	13
87	A retrospective study of S-1 and oxaliplatin combination chemotherapy in patients with refractory pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2013, 72, 985-990.	1.1	11
88	Deletion of Histone Methyltransferase G9a Suppresses Mutant Kras-driven Pancreatic Carcinogenesis. Cancer Genomics and Proteomics, 2020, 17, 695-705.	1.0	9
89	Protein intake after the initiation of chemotherapy is an independent prognostic factor for overall survival in patients with unresectable pancreatic cancer: A prospective cohort study. Clinical Nutrition, 2021, 40, 4792-4798.	2.3	8
90	A phase I trial of gemcitabine, S-1 and LV combination (GSL) therapy in advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2014, 74, 911-915.	1.1	7

#	Article	IF	Citations
91	Diagnostic yield of the plasma free amino acid index for pancreatic cancer in patients with diabetes mellitus. Pancreatology, 2019, 19, 695-698.	0.5	6
92	A phase II trial of gemcitabine, S-1 and LV combination (GSL) therapy in patients with advanced pancreatic cancer. Investigational New Drugs, 2019, 37, 338-344.	1.2	6
93	A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxel. Investigational New Drugs, 2021, 39, 605-613.	1.2	6
94	ABO Blood Group and Risk of Pancreatic Carcinogenesis in Intraductal Papillary Mucinous Neoplasms. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1020-1028.	1.1	6
95	Late-Evening Carbohydrate and Branched-Chain Amino Acid Snacks Improve the Nutritional Status of Patients Undergoing Hepatectomy Based on Bioelectrical Impedance Analysis of Body Composition. Gastrointestinal Tumors, 2019, 6, 81-91.	0.3	5
96	No Survival Benefit from the Inhibition of Reninâ€“Angiotensin System in Biliary Tract Cancer. Anticancer Research, 2016, 36, 4965-4970.	0.5	5
97	Cancer-derived VEGF plays no role in malignant ascites formation in the mouse. World Journal of Gastroenterology, 2005, 11, 5455.	1.4	5
98	Inhibition of transforming growth factor-Î² signaling in myeloid cells ameliorates aortic aneurysmal formation in Marfan syndrome. PLoS ONE, 2020, 15, e0239908.	1.1	4
99	Reduced p38 mitogen-activated protein kinase in donor grafts accelerates acute intestinal graft-versus-host disease in mice. European Journal of Immunology, 2005, 35, 2210-2221.	1.6	3
100	Helicobacter pylori antibody responsiveness and prevalence of gastric cancer among 10,000 consecutive endoscoped Japanese individuals. Gastroenterology, 1998, 114, A336-A337.	0.6	2
101	Effect of home enteral nutrition after pancreaticoduodenectomy. Nutrition, 2019, 60, 206-211.	1.1	2
102	Abstract 2065: DDX20 deficiency enhances NF-ÎºB by impairing NF-ÎºB suppressive-microRNA function and leads to hepatocarcinogenesis. , 2010, , .		1
103	Abstract 3978: DDX20, a suppressor of hepatocarcinogenesis, controls NF-ÎºB activity through regulating the function of miRNA-22 and miRNA-140-3p targeting transcriptional coactivators. , 2011, , .		1
104	Rescuing TGFb-Smad signalling pathway restores growth inhibition by TGFb in pancreatic cancer cells. Gastroenterology, 2000, 118, A47.	0.6	0
105	Rectosigmoid findings correlate with proximal colon adenoma but not with proximal colon cancer: A study of 3285 consecutive cases examined by total colonoscopy. Gastroenterology, 2001, 120, A603.	0.6	0
106	Frequent frameshift mutations of the RAD50 recombinational DNA repair gene in colorectal cancers with microsatellite instability. Gastroenterology, 2001, 120, A297.	0.6	0
107	Establishment of mouse model for analyzing Graft-Versus-Tumor(GVT) effect against gastrointestinal tumor. Gastroenterology, 2003, 124, A481.	0.6	0
108	Heat shock protein 60 binds to hepatitis B virus X protein (HBx) and enhances HBx-mediated apoptosis. Gastroenterology, 2003, 124, A762.	0.6	0

#	Article	IF	Citations
109	Altered Composition of Fatty Acids Exacerbates Hepato-Tumorigenesis Under Active Phosphatidylinositol 3-Kinase Pathway. Gastroenterology, 2011, 140, S-704.	0.6	0
110	Analysis of the Role of JNK and Therapeutic Effect of JNK Inhibition in Pancreatic Cancer. Gastroenterology, 2011, 140, S-35.	0.6	0
111	Quantitative Analysis of Hydroxymethylated DNA in Primary Colorectal Cancer. Gastroenterology, 2011, 140, S-819.	0.6	0
112	Genetically-engineered mouse pancreatic cancer models. Suizo, 2010, 25, 28-34.	0.1	0
113	Abstract 1184: Prognostic significance of genetic alterations detected by high-density single nucleotide polymorphism (SNP) array in gastrointestinal cancer. , 2010, , .		0
114	Abstract 2381: Preclinical molecular targeting therapy of pancreatic cancer using a genetically engineered mouse model. , 2011, , .		0
115	Abstract 3292: The exploration of novel strategy for treatment of pancreactic cancer using genetically engineered mice. , 2011, , .		0
116	Abstract 544: Blockade of CXC chemokines/CXCR2 axis in the tumor microenvironment as a potent therapeutic strategy for pancreatic ductal adenocarcinoma. , 2011, , .		0
117	Phase I study of a combination therapy of gemcitabine and candesartan in patients with advanced pancreatic cancer: GECA-1 study.. Journal of Clinical Oncology, 2011, 29, e14555-e14555.	0.8	0
118	Effect of non-anticancer drugs on prognosis of pancreatic cancer (PaC) receiving chemotherapy.. Journal of Clinical Oncology, 2012, 30, 309-309.	0.8	0
119	Abstract 851: Epidermal growth factor receptor inhibitor erlotinib prolongs survival inKras-mutant pancreatic ductal adenocarcinoma by inhibiting gemcitabine-induced mitogen activated protein kinase signaling activation. , 2012, , .		0
120	Abstract A39: The exploration of novel strategy for treatment of pancreactic ductal adenocarcinoma targeting tumor microenvironment with multi-kinase inhibitors. Clinical Cancer Research, 2012, 18, A39-A39.	3.2	0
121	Abstract A69: The novel strategy for treatment of pancreactic ductal adenocarcinoma targeting tumor microenvironment.. , 2013, , .		0
122	A retrospective analysis of early CA19-9 progression in salvage-chemotherapy for refractory pancreatic cancer.. Journal of Clinical Oncology, 2013, 31, e15146-e15146.	0.8	0
123	A phase 1 trial of GSL (gemcitabine, S-1, LV) combination therapy in advanced pancreatic cancer.. Journal of Clinical Oncology, 2014, 32, 290-290.	0.8	0
124	Associations between K-ras mutation, smoking, and prognosis of pancreatic cancer.. Journal of Clinical Oncology, 2014, 32, 298-298.	0.8	0
125	Which patients benefit from the inhibition of renin-angiotensin system in advanced pancreatic cancer? An exploratory analysis in 349 patients.. Journal of Clinical Oncology, 2014, 32, e15216-e15216.	0.8	0
126	Abstract B10: Epidermal growth factor receptor inhibitor prolongs survival in pancreatic cancer by blocking gemcitabine-induced mitogen-activated protein kinase signal. , 2014, , .		0

#	Article	IF	Citations
127	Abstract A55: A role of bone morphogenetic protein signaling in pancreatic cancer. , 2015, , .		0
128	Abstract 2301: The generation of colorectal cancer mouse model based on microsatellite instability and the identification of transforming growth factor-beta signal target. , 2015, , .		0
129	Abstract A40: Emergence of CD47- high expression cells confers enhanced tumorigenicity upon KDM6B suppression in pancreatic cancer. , 2016, , .		0
130	Abstract B66: BET inhibition remodels tumor stroma and suppresses progression of human pancreatic cancer. , 2016, , .		0
131	Abstract C47: Plasma ANP and soluble cell adhesion molecule X are novel risk factors for pancreatic cancer-associated thrombosis. , 2019, , .		0